Halozyme Therapeutics Inc... (HALO)

NASDAQ: HALO · Real-Time Price · USD

61.07

-0.35 (-0.57%)

At close: May 01, 2025, 11:45 AM

-0.57% (1D)

Bid	61
Market Cap	7.54B
Revenue (ttm)	1.02B
Net Income (ttm)	444.09M
EPS (ttm)	3.43
PE Ratio (ttm)	17.8
Forward PE	9.12
Analyst	Buy

Ask	61.09
Volume	268,067
Avg. Volume (20D)	1,454,972
Open	61.00
Previous Close	61.42
Day's Range	59.73 - 61.63
52-Week Range	38.88 - 66.00
Beta	1.32

About HALO

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules a...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 16, 2004

Employees 350

Stock Exchange NASDAQ

Ticker Symbol HALO

Website https://www.halozyme.com

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for HALO stock is "Buy." The 12-month stock price forecast is $64, which is an increase of 4.80% from the latest price.

Stock Forecasts

Next Earnings Release

Halozyme Therapeutics Inc. is scheduled to release its earnings on May 6, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+5.02%

Halozyme Therapeutics shares are trading higher af... Unlock content with Pro Subscription

5 months ago

+7.22%

Halozyme Therapeutics shares are trading higher after the company announced it withdrew plans to acquire Evotec.

News

Just now · seekingalpha.com

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

Halozyme Therapeutics, Inc. remains a buy due to its strong subscription-based business model, high growth, and undervaluation. HALO's robust product library, focused on drug delivery systems, positio...

2 days ago · zacks.com

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · investors.com

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market

Shares of biotech stock Halozyme found support at their 200-day line in a time where many stocks are below this level. The post Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatil...

1 month ago · zacks.com

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 month ago · fxempire.com

Halozyme Joins the $1 Billion Club

Halozyme Therapeutics, Inc. (HALO) shares up after passing $1 billion in revenue for first time, strong guidance.

1 month ago · investors.com

Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue

Halozyme stock is in a consolidation pattern but its chart shows an alternate entry. The biotech name hit two milestones in 2024.

1 month ago · zacks.com

HALO vs. AMGN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amgen (AMGN). But which of these two companies is the best option f...